Affiliation: University of California
- Priority medicines for maternal and child health: a global survey of national essential medicines listsSuzanne Hill
Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
PLoS ONE 7:e38055. 2012..The objective of this study was to examine the occurrence of these priority medicines on national essential medicines lists...
- Factors associated with results and conclusions of trials of thiazolidinedionesGail Rattinger
Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland at Baltimore, Baltimore, Maryland, United States of America
PLoS ONE 4:e5826. 2009....
- Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in EstoniaPille Taba
Department of Continuing Medical Education, University of Tartu, Puusepa 8, Tartu, 51014, Estonia
BMC Health Serv Res 12:455. 2012..The study was conducted to inform the revision of the clinical practice guideline development process and can provide inspiration to other countries considering the increasing use of evidence-based medicine...
- The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelinesLisa A Bero
Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA 94118, USA
J Clin Epidemiol 66:132-9. 2013..This experience may be relevant to other small or resource-limited countries...
- Association of trial registration with the results and conclusions of published trials of new oncology drugsNicolas Rasmussen
History and Philosophy of Science, University of New South Wales, Sydney 2052, Australia
Trials 10:116. 2009..This study compares the prevalence of favorable results and conclusions among published reports of registered and unregistered randomized controlled trials of new oncology drugs...
- Could chiropractors screen for adverse drug events in the community? Survey of US chiropractorsMonica Smith
Palmer Center for Chiropractic Research, Palmer College of Chiropractic, Davenport, IA, USA
Chiropr Osteopat 18:30. 2010....
- Evidence and argument in policymaking: development of workplace smoking legislationDorie E Apollonio
Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143 0613, USA
BMC Public Health 9:189. 2009..We sought to identify factors that affect the passage of public health legislation by examining the use of arguments, particularly arguments presenting research evidence, in legislative debates regarding workplace smoking restrictions...
- Implementation of a workplace smoking ban in bars: the limits of local discretionTheresa Montini
New York University, 423 East 23rd Street, VET 16N, New York, NY 10010, USA
BMC Public Health 8:402. 2008..In January 1998, the California state legislature extended a workplace smoking ban to bars. The purpose of this study was to explore the conditions that facilitate or hinder compliance with a smoking ban in bars...
- Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in ZambiaAnna L Ridge
Medicine Access and Rational Use, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
BMC Health Serv Res 10:340. 2010..The objective of this study was to identify barriers to the availability and use of MgSO4 in the Zambian Public Health System...
- Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than othersLisa Bero
Clinical Pharmacy and Health Policy, University of California, San Francisco, California, United States of America
PLoS Med 4:e184. 2007....
- "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterpriseLisa Bero
University of California, Clinical Pharmacy and Health Policy, 3333 California Street, Suite 420, San Francisco, CA, USA
J Clin Epidemiol 61:629-33. 2008
- To give is better than to receive: compliance with WHO guidelines for drug donations during 2000-2008Lisa Bero
Department of Clinical Pharmacy, University of California, 3333 California Street Suite 420, San Francisco, CA 94118, United States of America
Bull World Health Organ 88:922-9. 2010..to assess drug donations in terms of their adherence to the drug donation guidelines put forth by the World Health Organization (WHO)...
- An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciencesTracey J Woodruff
University of California, San Francisco, CA, USA
Health Aff (Millwood) 30:931-7. 2011..The methodology can also support professional societies, health care organizations, government agencies, and others in developing prevention-oriented guidelines for use in clinical and policy settings...
- Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analysesBETH HART
Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, 3333 California St, Suite 420, San Francisco, CA 94118, USA
BMJ 344:d7202. 2012..To investigate the effect of including unpublished trial outcome data obtained from the Food and Drug Administration (FDA) on the results of meta-analyses of drug trials...
- Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentationKristin Rising
School of Medicine, University of California San Francisco, San Francisco, California, USA
PLoS Med 5:e217; discussion e217. 2008....
- Interactions between non-physician clinicians and industry: a systematic reviewQuinn Grundy
Department of Social and Behavioral Sciences, School of Nursing, University of California, San Francisco, San Francisco, California, United States of America
PLoS Med 10:e1001561. 2013..The purpose of this systematic review is to examine the types and implications of non-physician clinician-industry interactions in clinical practice...
- Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomesNancy Nkansah
University of California San Francisco, 155 North Fresno Street Suite 224, Fresno, CA 93701, USA
Public Health Nutr 12:1931-7. 2009..To explore the relationship between industry sponsorship of Ca supplementation studies in healthy children and study outcomes...
- Strategies for obtaining unpublished drug trial data: a qualitative interview studyNicole Wolfe
Department of Social and Behavioral Sciences, University of California, San Francisco, CA 94118, USA
Syst Rev 2:31. 2013....
- Medicaid drug selection committees and inadequate management of conflicts of interestNicole Yvonne Nguyen
Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, 3333 California St, San Francisco, CA 94118, USA
JAMA Intern Med 173:338-43. 2013....
- Tobacco industry research and protection of human subjects: a case study of R. J. ReynoldsJenny White
Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
Nicotine Tob Res 9:1213-25. 2007..Policymakers should consider expanding the scope of federal human subjects research regulations to cover research undertaken by private firms such as tobacco companies...
- Financial ties and conflicts of interest between pharmaceutical and tobacco companiesBhavna Shamasunder
Institute for Health Policy Studies, University of California, San Francisco, USA
JAMA 288:738-44. 2002..Thus, because tobacco cessation product marketing has been altered as a result of these financial conflicts, disclosure would serve the interest of public health...
- Interventions for tobacco use cessation in people in treatment for or recovery from substance use disordersDorie Apollonio
Clinical Pharmacy, University of California San Francisco, 3333 California Street, Suite 420, San Francisco, CA, USA, 94143 0613
Cochrane Database Syst Rev 11:CD010274. 2016....
- Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic reviewDavid Krauth
Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA 94118, USA
Environ Health Perspect 121:985-92. 2013..However, there is significant debate about how to evaluate the methodology and potential biases of the animal studies. There is no agreed-upon approach, and a systematic evaluation of current best practices is lacking...
- Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysisDavid Krauth
Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, United States of America
PLoS Biol 12:e1001770. 2014..Possible reasons for the differences between nonindustry- and industry-sponsored studies, such as selective reporting of outcomes, require further study. ..
- Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysisAndrew T Anglemyer
Department of Clinical Pharmacy, University of California San Francisco, 50 Beale Street, San Francisco, CA, 94143, USA
BMC Med Res Methodol 15:12. 2015..In the present analysis, we evaluated the impact of funding source on publication bias in animal studies estimating the effect of statins on atherosclerosis and bone outcomes...
- Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trialsAndrew Anglemyer
Global Health Sciences, University of California, San Francisco, San Francisco, California, USA, 94105
Cochrane Database Syst Rev 4:MR000034. 2014....
- Outcome reporting in industry-sponsored trials of gabapentin for off-label useS Swaroop Vedula
Center for Clinical Trials, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
N Engl J Med 361:1963-71. 2009..There is good evidence of selective outcome reporting in published reports of randomized trials...
- Availability, prices and affordability of the World Health Organization's essential medicines for children in GuatemalaAngela Anson
Department of Clinical Pharmacy, University of California, San Francisco, CA 94143 0622, USA
Global Health 8:22. 2012..A first step in achieving this goal is to obtain a baseline measure of access to essential medicines. The objective of this project was to measure the availability, prices, and affordability of children's medicines in Guatemala...
- Implications of the tobacco industry documents for public health and policyLisa Bero
Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, California 94143 0613, USA
Annu Rev Public Health 24:267-88. 2003..The paper concludes with a discussion of the implications of tobacco document research for public health and the application of such research to fields other than tobacco control...
- Applying the essential medicines concept to US preferred drug listsTimothy P Millar
Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
Am J Public Health 101:1444-8. 2011..We also characterized listed medicines by generic availability and appearance on treatment guidelines...
- Clarification of study and citationPatrick R Finley
Arch Intern Med 167:2531; author reply 2531-2. 2007